Paper Review Records
All Paper Review Records
14 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
59
days
Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024
AuthorsJane L. Meisel; Clara Chen; Ayush Kris; Meng Ru; Timothy Pham; James Roose
Affiliations1. Department of Hematology and Medical Oncology, Emory Winship Cancer Institute, Emory University, Atlanta, USA; 2. AstraZeneca, Gaithersburg, USA; 3. Flatiron Health, New York, USA
103
days
Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study
AuthorsJingze Liu; Linxiaoxiao Ding; Jiayi Wang; Tao Chen; Tianzhu Long; Qian Li; Jie Chai; Herui Yao; Ying Wang; Jianli Zhao
Affiliations1. Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, P. R. China; 2. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; 3. Thyroid and Breast Surgery Department, Guangzhou Women and Children’s Medical center, Guangzhou Medical University, Guangzhou, China
119
days
Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes
AuthorsMatthew R. Kroll; Mary C. Schroeder; Joan M. Neuner; Brahmendra R. Viyyuri; Aditya Ravindra; Dana McDougall; Cole G. Chapman; Nicole M. G. Fleege; Elizabeth A. Chrischilles; Xing Song; Sneha Phadke
Affiliations1. Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, USA; 2. Division of Health Services Research, Department of Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, USA; 3. Division of General Internal Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA; 4. MercyOne Waterloo Hematology/Oncology, Waterloo, USA; 5. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, USA; 6. Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, University of Missouri School of Medicine, Columbia, USA
185
days
Real-world estrogen receptor alpha 1 ( ESR1 ) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018–2024
AuthorsJane Meisel; Tim Pham; Clara Chen; Ayush Kris; James Roose
Affiliations1. Department of Hematology and Medical Oncology, Emory Winship Cancer Institute, Emory University, Atlanta, GA, USA; 2. AstraZeneca, Gaithersburg, MD, USA; 3. Flatiron Health, New York, USA
99
days
Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study
AuthorsQian Chen; Ian Campbell; Mark Elwood; Alana Cavadino; Phyu Sin Aye; Sandar Tin Tin
Affiliations1. Department of Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; 2. Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; 3. Department of Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; 4. Division of Health, University of Waikato, Hamilton, New Zealand; 5. Cancer Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford, UK
191
days
Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival
AuthorsEmily L. Podany; Lorenzo Foffano; Lorenzo Gerratana; Arielle J. Medford; Natalie K. Heater; Eleonora Nicolò; Shaili Tapiavala; Letizia Pontolillo; Annika Putur; Diana A. Jaber; Katherine Clifton; Nitin Katakam; Sarah Addison; Marla Lipsyc-Sharf; Carolina Reduzzi; Foluso O. Ademuyiwa; Fabio Puglisi; William J. Gradishar; Cynthia X. Ma; Aditya Bardia; Massimo Cristofanilli; Andrew A. Davis
Affiliations1. Department of Medicine, Washington University in St. Louis, St. Louis, USA; 2. Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy; 3. Department of Medicine, University of Udine, Udine, Italy; 4. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, USA; 5. Department of Medicine, Northwestern University, Chicago, USA; 6. Department of Medicine, Weill Cornell Medicine, New York, USA; 7. Medical Oncology, Department of Translational Medicine and Surgery, Universitá Cattolica del Sacro Cuore, Rome, Italy; 8. Department of Medicine, UCLA Health, Los Angeles, USA
93
days
Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study
AuthorsZhenluan Tian; Hengyu Li; Yuxin Deng; Herui Yao; Ying Wang; Liang Jin; Heran Deng; Na Chen; Jieqiong Liu
Affiliations1. Department of Breast Tumour Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; 2. Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; 3. Department of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University (Second Military Medical University), Shanghai, China; 4. Department of Breast Surgery, Shenshan Medical Center, Memorial Hospital of Sun Yat-sen University, Shanwei, China
135
days
Body mass index-associated gut microbial taxa and functional pathways in women with benign and malignant breast disease
AuthorsJack W. Sample; Stephen Johnson; Tanya L. Hoskin; Matteo Redaelli; Marina R. Walther-Antonio; Jun Chen; Amy C. Degnim; Tina J. Hieken
Affiliations1. Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, USA; 2. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, USA; 3. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, USA; 4. Mayo Clinic Comprehensive Cancer Center, Rochester, USA
140
days
Validation of a novel prognostic staging system for breast cancer incorporating age at diagnosis
AuthorsHelen M. Johnson; Wenli Dong; Yu Shen; William Irish; Jan H. Wong; Nasreen A. Vohra; Nina Tamirisa
Affiliations1. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA; 3. Department of Surgery, Brody School of Medicine at East Carolina University, Greenville, USA
27
days
When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction
AuthorsTyler P. Shern; Victoria Chamberlain; Logan R. Holt; Michele A. Gadd; Francys C. Verdial; Tolga Ozmen; Michelle C. Specht; Charles S. Dai; Barbara L. Smith
Affiliations1. Division of Breast Surgery, Mass General Brigham, Boston, USA; 2. Division of Hematology Oncology, Mass General Brigham Cancer Institute, Boston, USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days